

TISSUE EXAM - Details

Results

Case Report

CASE REPORT

Surgical Pathology Report

Case: SSW-19-22738

Authorizing Provider: Marks, Leonard S., MD
10/03/2019 0922

Collected:

Ordering Location: CLARK UROLOGY
10/03/2019 1215

Received:

Pathologist: Ye, Huihui, MD, MS

Specimens: A) - Prostate, LLB 1

B) - Prostate, LLM 2

C) - Prostate, LLA 3

D) - Prostate, LB 4

E) - Prostate, LM 5

F) - Prostate, LA 6

G) - Prostate, RB 7

H) - Prostate, RM 8

I) - Prostate, RA 9

J) - Prostate, RLB 10

K) - Prostate, RLA 12

midgland L) - Prostate, 13-1 Target Right posterolateral peripheral

midgland M) - Prostate, 13-2 Target Right posterolateral peripheral

midgland N) - Prostate, 13-3 Target Right posterolateral peripheral

midgland O) - Prostate, 13-4 Target Right posterolateral peripheral

CLINICAL INFORMATION

62-year-old male with an elevated PSA. His PSA was 3.5 in June 2019, down from 5.3 in April 2019. In April he had 9.4% free psa. He does not have a family history of prostate cancer; however he is on testosterone replacement therapy and in II days inhibitor usage.

His select MDX score put him at 14% risk of Gleason grade group 2 or higher prostate cancer. MRI dated 08/16/2019 revealed 31 gram prostate with a Grade 4 target at right posterolateral peripheral midgland.

Lab Results:

Component
PSATOTAL

Value
4.8 (H)

Date
07/25/2019

FINAL DIAGNOSIS**PROSTATE, CORE BIOPSY:****Systematic Biopsies**

Site	Diagnosis	Tumor								
		GS (GG)	% core	mm	Max %G4	Crib4	IDC	PNI	# core	Note
A. LLB	AGFHI									See Note
B. LLM	PCA	3+3=6 (1)	25% DI	2 mm DI					1/1	
C. LLA	PCA	4+3=7 (3)	40% DI	4 mm	60%				1/1	See Note
D. LB	PCA	3+3=6 (1)	40% DI	5 mm DI				Present	1/1	
E. LM	AGFHI									PIN4; See Note
F. LA	Benign									
G. RB	Benign									
H. RM	Benign									
I. RA	AGFHI									See Note
J. RLB	AGFHI									See Note
K. RLA	PCA	3+3=6 (1)	20%	2 mm					1/1	

*Note: Additional levels examined for parts A, C, E, I, and J. Tissue not present on deeper levels in part E and J. Tumor is best seen on deeper levels in part C.

Targeted Biopsies

Site	Diagnosis	Tumor								
		GS (GG)	% core	mm	Max %G4	Crib4	IDC	PNI	# Core	Note
L. 13-1 T-RPPM	PCA	4+3=7 (3)	20%	2 mm	60%				1/1	See Note
M. 13-2 T-RPPM	PCA	3+3=6 (1)	20%	2 mm					1/1	
N. 13-3 T-RPPM	HGPIN, AGF									PIN4; See Note
O. 13-4 T-RPPM	Benign									

*Note: Additional levels examined for parts L and N.

Site Acronyms:

LLB= Left lateral base
 LLM= Left lateral mid
 LLA= Left lateral apex
 LB= Left base
 LM= Left mid
 LA= Left apex
 RLB=Right lateral base
 RLM= Right lateral mid
 RLA= Right lateral apex
 RB= Right base
 RM= Right mid
 RA= Right apex

T-RPPM = Target Right posterolateral peripheral midgland

Diagnosis Acronyms:

PCA = Prostatic adenocarcinoma
 AGF = Atypical glandular focus
 AGFHI = Atypical glandular focus, suspicious for carcinoma.
 Benign = Benign prostatic tissue
 BFM = Benign fibromuscular tissue, no prostatic tissue seen
 HGPIN = High grade prostatic intraepithelial neoplasia
 PINAGF = High grade prostatic intraepithelial neoplasia with adjacent atypical glandular focus
 DI= in a discontinuous manner
 PIN4 = PIN4 immunostain was performed with adequate controls. The results support the diagnosis.

Header Acronyms:

GS = Gleason score
 GG = Grade group
 % core = % of the core involved by tumor
 mm = Length in mm involved by tumor
 Max %G4 = Maximum % of Gleason pattern 4
 Crib4 = Large cribriform Gleason pattern 4
 IDC = Intraductal carcinoma
 PNI = Perineural invasion
 # core = # of positive cores / # of cores submitted

MICROSCOPIC DESCRIPTION

A microscopic examination has been performed.

IHC REPORT

BLOCK: E1

ANTIBODY/PROBE: **RESULT (IN AREAS OF INTEREST)/COMMENT**
 PIN4 Noncontributory, lesion of interest disappeared on IHC

BLOCK: N1

ANTIBODY/PROBE: **RESULT (IN AREAS OF INTEREST)/COMMENT**
 PIN4 Positive for racemase; positive for p63 and HMWCK

INTERPRETATION:

See final diagnosis.

Note: The immunoperoxidase stain reported above was developed and its performance characteristics determined by UCLA Medical Center Clinical Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration, although such approval is not required for analyte-specific reagents of this type. Appropriate positive and negative controls are included for each case.

GROSS DESCRIPTION

The specimens are received in 15 formalin containers, labeled with the

SPECIMEN SUMMARY

Site	Pieces	Description	Spec Len (cm)
[A] LEFT LATERAL BASE	3	pink-white	ranging from 0.1 to

			1.6
[B] LEFT LATERAL MID	2	white-yellow	1.7, 0.1
[C] LEFT LATERAL APEX	2	white-pink	1.3, 0.1
[D] LEFT BASE	1	white-pink	2.1
[E] LEFT MID	2	white-pink	1.7, 0.4
[F] LEFT APEX	3	pink-white	ranging from 0.2 to 2.0
[G] RIGHT BASE	2	red-white	1.7, 0.4
[H] RIGHT MID	3	pink-white	ranging from 0.1 to 1.6
[I] RIGHT APEX	1	white-yellow	2.6
[J] RIGHT LATERAL BASE	1	red-white	1.4
[K] RIGHT LATERAL APEX	2	red-white	1.6, 0.2
[L] 13-1 TARGET RIGHT POSTEROLATERAL PERIPHERAL MIDGLAND	2	pink-white	1.6, 0.1
[M] 13-2 TARGET RIGHT POSTEROLATERAL PERIPHERAL MIDGLAND	1	white-yellow	2.0
[N] 13-3 TARGET RIGHT POSTEROLATERAL PERIPHERAL MIDGLAND	2	white-yellow	1.8, 0.1
[O] 13-4 TARGET RIGHT POSTEROLATERAL PERIPHERAL MIDGLAND	1	white-yellow	2.1

ND/ajs 10/03/2019

Signatures

I certify that I personally conducted a gross and/or microscopic examination(s) of the described specimen(s), and have reviewed the interpretation of this test and diagnosis(es). I agree with the documented findings or edited the findings as necessary.

Electronically signed by Ye, Huihui, MD, MS on 10/10/2019 at 5:31 PM

Encounter-Level Documents - 10/03/2019:

Document on 10/3/2019 1657 by Ambrosio, Arianne Mclat : After Visit Summary

Document on 10/3/2019 0922 by Marks, Leonard S., MD : After Visit Summary